The Manufacturers Life Insurance Company Purchases Shares of 13,221 Design Therapeutics, Inc. (NASDAQ:DSGN)

The Manufacturers Life Insurance Company purchased a new position in shares of Design Therapeutics, Inc. (NASDAQ:DSGN) in the third quarter, according to its most recent filing with the SEC. The firm purchased 13,221 shares of the company’s stock, valued at approximately $71,000.

Other hedge funds have also recently made changes to their positions in the company. SG Americas Securities LLC bought a new stake in shares of Design Therapeutics during the 3rd quarter valued at about $66,000. American Century Companies Inc. acquired a new position in Design Therapeutics in the second quarter valued at approximately $71,000. Cubist Systematic Strategies LLC boosted its holdings in shares of Design Therapeutics by 75.6% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 23,497 shares of the company’s stock worth $79,000 after buying an additional 10,113 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Design Therapeutics during the 2nd quarter worth approximately $81,000. Finally, Palumbo Wealth Management LLC increased its stake in shares of Design Therapeutics by 11.3% in the 3rd quarter. Palumbo Wealth Management LLC now owns 36,774 shares of the company’s stock valued at $198,000 after acquiring an additional 3,720 shares in the last quarter. 56.64% of the stock is owned by institutional investors.

Design Therapeutics Stock Down 0.6 %

Design Therapeutics stock opened at $6.25 on Wednesday. The company has a market capitalization of $353.88 million, a PE ratio of -7.35 and a beta of 1.86. Design Therapeutics, Inc. has a 12-month low of $2.24 and a 12-month high of $7.77. The firm’s fifty day moving average is $5.83 and its 200 day moving average is $4.95.

About Design Therapeutics

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.